相关实验视频
Updated: Jan 7, 2026

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.3K
实施基于医疗记录的多医院电子胰岛素订单,以减少低血糖事件
Domenic DiSanti1,2, April Goley2, Avni Garg2
1Department of Diabetes, Endocrinology and Metabolism, University of Nebraska Medical Center, Omaha, Nebraska.
AACE endocrinology and diabetes
|December 30, 2025
概括
实施标准化的电子胰岛素订单集显著减少了糖尿病住院患者的低血糖事件. 这项质量改进倡议改善了血糖控制,并证明了在住院糖尿病管理中标准化方案的价值.
科学领域:
- 内部医学 内部医学
- 内分泌学 在内分泌学.
- 提高质量 提高质量
背景情况:
- 患有糖尿病的住院患者的血糖控制具有挑战性,低血糖会增加风险.
- 标准化的胰岛素订单可以改善血糖管理,减少不良事件.
研究的目的:
- 评估基于电子医疗记录的强制性胰岛素订单对住院患者的低血糖和高血糖的影响.
- 评估胰岛素订单准确性和遵守最佳实践的改进.
主要方法:
- 一个质量改进项目在10家医院实施了一套标准化胰岛素订单.
- 订单组包括因胰岛素与营养不匹配的故障保护,基底/囊覆盖率和剂量准确性.
- 主要结局是每1000个患者日的低血糖几天;次要结局包括高血糖和血红蛋白A1c数量.
主要成果:
- 在10个地点中的9个,低血糖日减少了24% (每1000个患者日13到10,P<0.01).
- 超血糖几天减少了16% (每1000个患者日90到76,P < .01).
- 血红蛋白A1c排序提高了12% (60%至67%,P < .01).
结论:
- 一个强制性的,标准化的电子胰岛素订单组有效地减少了住院患者的低血糖症.
- 该协议在住院糖尿病管理中具有价值,尽管特定地点的变化表明需要量身定制的方法.
相关概念视频
SBAR II: Application of SBAR
5.6K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
5.6K
Hypoglycemia and Glucagon
763
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
763
Insulin: Dosing Regimen and Adverse Effects
644
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
644
Insulin Formulations: Types and Delivery
597
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
597
Oral Hypoglycemic Agents: Glinides
554
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
554
Dipeptidyl Peptidase 4 Inhibitors
540
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
540

